4Sc AG - ESG Rating & Company Profile powered by AI
This dashboard includes a questions and answers table for 4Sc AG. This ESG rating includes seventeen United Nations Sustainable Development Goals including: 'Good Health & Wellbeing', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'. This analysis of 4Sc AG was assembled by All Street Sevva using advanced AI.
4Sc AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 2.7, social score of 3.2 and governance score of 6.0.
4.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
989 | Tricida Inc | 4.1 | High |
1004 | 4Sc AG | 4.0 | High |
1004 | Can B Corp | 4.0 | High |
1004 | CLS Holdings USA Inc | 4.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does 4Sc AG have an accelerator or VC vehicle to help deliver innovation?
Does 4Sc AG disclose current and historical energy intensity?
Does 4Sc AG report the average age of the workforce?
Does 4Sc AG reference operational or capital allocation in relation to climate change?
Does 4Sc AG disclose its ethnicity pay gap?
Does 4Sc AG disclose cybersecurity risks?
Does 4Sc AG offer flexible work?
Does 4Sc AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does 4Sc AG disclose the number of employees in R&D functions?
Does 4Sc AG conduct supply chain audits?
Does 4Sc AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does 4Sc AG conduct 360 degree staff reviews?
Does 4Sc AG disclose the individual responsible for D&I?
Does 4Sc AG disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does 4Sc AG disclose current and / or historical scope 2 emissions?
Does 4Sc AG disclose water use targets?
Does 4Sc AG have careers partnerships with academic institutions?
Did 4Sc AG have a product recall in the last two years?
Does 4Sc AG disclose incidents of discrimination?
Does 4Sc AG allow for Work Councils/Collective Agreements to be formed?
Has 4Sc AG issued a profit warning in the past 24 months?
Does 4Sc AG disclose parental leave metrics?
Does 4Sc AG disclose climate scenario or pathway analysis?
Does 4Sc AG disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does 4Sc AG disclose the pay ratio of women to men?
Does 4Sc AG support suppliers with sustainability related research and development?
Does 4Sc AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does 4Sc AG reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is 4Sc AG involved in embryonic stem cell research?
Does 4Sc AG disclose GHG and Air Emissions intensity?
Does 4Sc AG disclose its waste policy?
Does 4Sc AG report according to TCFD requirements?
Does 4Sc AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does 4Sc AG disclose energy use targets?
Does 4Sc AG disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does 4Sc AG have a policy relating to cyber security?
Have a different question?
Potential Risks for 4Sc AG
These potential risks are based on the size, segment and geographies of the company.
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.